Karyopharm Grants Equity Awards to Four New Hires

The awards were issued under the company’s 2022 Inducement Stock Incentive Plan. According to the filing, the equity follows a standard three-year vesting schedule, with one-third of the units becoming available on each of the three consecutive anniversaries of the grant date. Retention of these units remains contingent upon the recipients maintaining their status as active employees or service providers to the pharmaceutical firm through each designated vesting period.

Karyopharm continues to focus its commercial efforts on its primary asset, the nuclear export inhibitor XPOVIO, which is currently marketed for relapsed or refractory multiple myeloma. The company operates from its headquarters in Massachusetts, managing a pipeline that includes ongoing research into hematologic and solid tumor cancers, such as myelofibrosis and endometrial cancer.